Phaseline

Companies › Alfasigma

Alfasigma: clinical trials, targets and expected readouts

1 active drug program in 7 registered trials: 4 Phase 3, 2 Phase 4, 1 Phase 2; Immunology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Filgotinib
Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase TYK2 inhibitor
JAK1, JAK2, TYK2, JAK3Phase 3Polyarticular Course Juvenile Idiopathic Arthritis; Juvenile Idiopathic Arthritis (JIA); Ulcerative Colitis; Axial Spondyloarthritis …Jun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04985435FilgotinibPhase 4Rheumatoid ArthritisImmunologySep 2025
NCT06285539FilgotinibPhase 2Behcet's DiseaseImmunologyDec 2026
NCT07554495FilgotinibPhase 3Polyarticular Course Juvenile Idiopathic ArthritisImmunologyJun 2027
NCT07553182FilgotinibPhase 3Juvenile Idiopathic Arthritis (JIA)ImmunologyDec 2027
NCT06865417FilgotinibPhase 3Ulcerative ColitisImmunologyJun 2028
NCT05785611FilgotinibPhase 3Axial SpondyloarthritisImmunologyDec 2028
NCT06687551FilgotinibPhase 4Rheumatoid Arthritis (RAImmunologyApr 2029

Targets

JAK1 (1) JAK2 (1) TYK2 (1) JAK3 (1)

Companies with the same targets

AbbVie Pfizer Incyte Sun Pharmaceutical Industries Takeda LEO Pharma Eisai Suzhou Zelgen Biopharmaceuticals Chia Tai Tianqing Pharmaceutical Group Chengdu Zenitar Biomedical Technology

Companies built like this

Sun Pharma Japan Alumis Pharvaris Netherlands AUG Therapeutics Lynk Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.